| Symbol
| MMP7
| contributors: mct/pgu - updated : 20-03-2015
|
| HGNC name
| matrix metallopeptidase 7 (matrilysin, uterine)
|
| HGNC id
| 7174
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
|
| gain of function
| |
with ETS1 in hepatocellular carcinomas | | tumoral
|
|
| --over
|
| |
in colorectal cancer with metastasis | | tumoral
|
|
|
| gain of function
| |
differentially up-regulated in germ cells teratomas | | constitutional
|
|
| --over
|
|
in epithelium by bacterial infection, inflammation and fibrosis  | | constitutional
|
|
| --over
|
| |
in congenital renal dysplasia (RD) | |
| Susceptibility
|
to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma |
| Variant & Polymorphism
SNP
, other
| polymorphism in the promoter increasing susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma |
|
snp Gly137Asp confers risk of liver cirrhosis |
|
functional variants of MMP7 are associated with susceptibility to H.pylori-induced precancerous gastric lesions |
| 
|
| Candidate gene
| positive expression may serve as a predictor of lymph node metastasis in gastric cancer |
|
elevated expression is predictor of disease recurrence of colon cancer and is related to decreased survival |
|
higher expression of MMP7 supports the notion of a role in the growth of lung carcinoma |
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | | | |
| develop MMP7-targeted novel anti-cancer drugs that block specifically the membrane-associated proteolytic action of this MMP, thereby having restricted side effects | | cancer | reproductive | breast | |
| may be a useful therapeutic target for treatment of this disease |
| | |
|
| Paneth cells (in mice) | |
MMP7(-/-) mice are resistant to LPS-induced lethality and that this resistance is correlated with reduced levels of systemic cytokines |